Hoth Therapeutics Inc
NASDAQ:HOTH
Hoth Therapeutics Inc
NASDAQ:HOTH
Price:
0.8987
USD
1.4%
Market Cap:
$13.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
US |
|
Jayden Resources Inc
XTSX:JDN
|
CA |
|
Lynas Rare Earths Ltd
XMUN:LYI
|
AU |
|
Kuber Resources Corp
OTC:KUBR
|
HK |
|
Capstone Copper Corp
TSX:CS
|
CA |
|
Prodigy Gold NL
ASX:PRX
|
AU |
|
D
|
Dimeco Inc
OTC:DIMC
|
US |
|
Hua Nan Financial Holdings Co Ltd
TWSE:2880
|
TW |
|
X
|
Xinjiang Tianrun Dairy Co Ltd
SSE:600419
|
CN |
|
World Precision Machinery Ltd
SGX:B49
|
CN |
|
Persimmon PLC
LSE:PSN
|
UK |
|
EPack Prefab Technologies Ltd
NSE:EPACKPEB
|
IN |
|
A
|
Alujain Corp
SAU:2170
|
SA |
|
F
|
FinecoBank Banca Fineco SpA
MIL:FBK
|
IT |
|
C
|
Creative Global Technology Holdings Ltd
NASDAQ:CGTL
|
HK |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of HOTH.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
HOTH
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
HOTH Competitors Multiples
Hoth Therapeutics Inc Competitors
Hoth Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
13.6m USD | 0 | -1.1 | -0.5 | -0.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
865.7B USD | 13.1 | 41.3 | 27.9 | 29.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
577.7B USD | 6.2 | 21.6 | 15 | 18.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.4 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD | 4.5 | 16.2 | 10 | 12.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP | 4.9 | 28.1 | 15.6 | 22 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.5B CHF | 5.2 | 21.1 | 13.1 | 16.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.1B USD | 2.5 | 20.2 | 7.8 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.6B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
